Nanopore sequencing as a cutting-edge technology for medulloblastoma classification

Area of Science:

• Genomics
• Oncology
• Bioinformatics

Background:

• Medulloblastoma (MB) is a prevalent embryonal malignant brain tumor with established molecular subgroups (WNT, SHH, Group 3, Group 4).
• Recent classifications reveal numerous MB subtypes, some associated with poor prognosis, necessitating improved diagnostic and management strategies.
• Accurate subtyping is crucial for balancing treatment efficacy with the risk of comorbidities in MB patients.

Purpose of the Study:

• To evaluate Nanopore sequencing for generating clinically relevant methylation and copy number profiles in medulloblastoma.
• To assess the accuracy and efficiency of Nanopore sequencing in subtyping medulloblastoma compared to established methods.

Main Methods:

• Nanopore sequencing was applied to two cohorts of medulloblastoma (MB) samples (n=44 and n=116).
• Performance was benchmarked against the gold standard EPIC array.
• Cost-effectiveness and speed were evaluated using Flongle flow cells.

Main Results:

• Nanopore sequencing achieved high accuracy in subgrouping MB, classifying 95.5% (42/44) and 91.4% (106/116) of tumors correctly.
• Rapid and cost-effective analysis using Flongle flow cells correctly classified 94.4% (17/18) of MB.
• Overall, Nanopore sequencing accurately subtyped 93.3% (28/30) of MB samples.

Conclusions:

• This study confirms Nanopore sequencing's suitability for medulloblastoma classification, representing the largest cohort analyzed to date.
• The technology demonstrates robust capacity for precise MB subtyping, a critical advancement for patient stratification in clinical trials.
• Nanopore sequencing offers a rapid, cost-effective, and transformative approach to medulloblastoma classification.